Misoprostol dose-related shivering and pyrexia in the third stage of labour. WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour.
OBJECTIVE
To select the misoprostol dose to be used in a large multicentre randomised trial comparing misoprostol with oxytocin in the routine management of the third stage of labour.


METHODS
Randomised pilot trial, double-blinded with the use of double placebos.


METHODS
Two of the nine hospitals that will participate in the main multicentre trial. The hospitals were located in Johannesburg, South Africa and Khon Kaen, Thailand.


METHODS
Women during second stage of labour about to be delivered vaginally.


METHODS
The trial had three arms: misoprostol 400 microg versus misoprostol 600 microg versus intramuscular oxytocin 10 IU. Each group received an injection and three tablets immediately after the birth of the baby.


METHODS
Shivering and pyrexia rates were the main outcome measures. Data on other side effects and characteristics of the third stage of labour were also collected. Side effects were noted as none, mild, moderate or severe.


RESULTS
Both shivering and pyrexia (temperature > 38 degrees C) were most common in the 600 microg misoprostol group (28% and 7.5% for shivering and pyrexia, respectively) compared with 400 microg misoprostol (19% and 2%), and the oxytocin group (12.5% and 3%). The increase in shivering in the misoprostol 600 microg group was due primarily to a higher rate of moderate shivering. None of the women had a temperature > 40 degrees C. There were no increases in severe side effects and other adverse events in the misoprostol 600 microg group.


CONCLUSIONS
When used in the management of the third stage of labour oral misoprostol is associated with an increase in the rate of moderate shivering and pyrexia which seems to be dose-related. Based on the results of this pilot trial, the Steering Committee has decided to use 600 microg misoprostol in the main trial, comparing it with oxytocin, in order to achieve higher effectiveness.
Lumbiganon
P
P
Khon Kaen University, Thailand.
Hofmeyr
J
J
Gülmezoglu
A M
AM
Pinol
A
A
Villar
J
J
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects*; D007744:Obstetric Labor Complications / Q000139:chemically induced*; D010120:Oxytocics / Q000008:administration & dosage / Q000009:adverse effects*; D010121:Oxytocin / Q000009:adverse effects; D010865:Pilot Projects; D011247:Pregnancy; D012768:Shivering / Q000187:drug effects*
D010120:Oxytocics; D016595:Misoprostol; D010121:Oxytocin